Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3283-3294

  Mahajan, Sumit S ^a   Scian, Michele ^b   Sripathy, Smitha ^a   Posakony, Jeff ^a,c   Lao, Uyen ^a   Loe, Taylor K ^a   Leko, Vid ^a   Thalhofer, Angel ^a   Schuler, Aaron D ^a,d   Bedalov, Antonio ^a   Simon, Julian A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Kineta Inc   (United States)

^d SYNTRIX BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2 BROMO 6 HYDROXYQUINOLIN 5 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 CHLORO 6 HYDROXY 4 METHYLQUINOLIN 5 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 CHLORO 6 HYDROXYQUINOLIN 5 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 CHLORO 6 HYDROXYQUINOLIN 5 YL)METHYL] 5 (4 PROPAN 2 YL)PHENYL] 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXY 3 METHOXYNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXY 6 METHOXYNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXY 6 METHYLNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXY 6 PHENYLNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 PHENYL 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 [4 (TRIFLUOROMETHYL) PHENYL] 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(2 HYDROXYNAPHTHALEN1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(3 BROMO 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(6 BROMO 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 2 METHYL 3 (4 METHYLPHENYL) 2,5 DIHYDRO 1,2 OXAZOL 5 ONE; 4 [(6 BROMO 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 3 (4 METHYLPHENYL) 2,5 DIHYDRO 1,2 OXAZOL 5 ONE; 4 [(6 BROMO 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(6 BROMO 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 PHENYL 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(6 ETHYL 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(6 HYDROXYQUINOLIN 5 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 4 [(7 BBROMO 2 HYDROXYNAPHTHALEN 1 YL)METHYL] 5 (4 METHYLPHENYL) 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 5 (3 BROMOPHENYL) 4 [(2 HYDROXYNAPHTHALEN1 YL)METHYL] 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 5 (4 BROMOPHENYL) 4 [(2 HYDROXYNAPHTHALEN1 YL)METHYL] 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 5 (4 FLUOROPHENYL) 4 [(2 HYDROXYNAPHTHALEN 1 YL)METHYL] 2,3 DIHYDRO 1H PYRAZOL 3 ONE; 6 HYDROXY 5 ([5 (4 METHYLPHENYL) 3 OXO 2,3 DIHYDRO 1H PYRAZOL 4 YL]METHYL)NAPHTHALENE 2 CARBONITRILE; HYDROLASE INHIBITOR; ISOXAZOL 5 ONE CAMBINOL DERIVATIVE; NAPHTHALENE DERIVATIVE; NAPHTHYL PYRIMIDINEDIONE; PYRAZOLONE; SIRTUIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTILYMPHOMA ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DISCOVERY; ISOXAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; NAPHTHALENES; PYRAZOLONES; PYRIMIDINONES; SIRTUINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899500104     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4018064     Document Type: Article

References (31)

1. Heltweg, B.; Gatbonton, T.; Schuler, A. D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; Depinho, R. A.; Gu, Y.; Simon, J. A.; Bedalov, A. Antitumor activity of a small-molecule inhibitor of human silent inform ation regulator 2 enzymes Cancer Res. 2006, 66, 4368-4377
2. Aljada, A.; Dong, L.; Mousa, S. A. Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications Curr. Opin. Investig. Drugs 2010, 11, 1158-1168
3. Sanchez-Fidalgo, S.; Villegas, I.; Sanchez-Hidalgo, M.; de la Lastra, C. A. Sirtuin modulators: mechanisms and potential clinical implications Curr. Med. Chem. 2012, 19, 2414-2441
4. Roth, M.; Chen, W. Y. Sorting out functions of sirtuins in cancer Oncogene 2014, 33, 1609-1620
5. Mahajan, S. S.; Leko, V.; Simon, J. A.; Bedalov, A. Sirtuin modulators Handb. Exp. Pharmacol. 2011, 206, 241-255
6. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. Drug Discovery 2006, 5, 493-506
7. Burnett, C.; Valentini, S.; Cabreiro, F.; Goss, M.; Somogyvari, M.; Piper, M. D.; Hoddinott, M.; Sutphin, G. L.; Leko, V.; McElwee, J. J.; Vazquez-Manrique, R. P.; Orfila, A. M.; Ackerman, D.; Au, C.; Vinti, G.; Riesen, M.; Howard, K.; Neri, C.; Bedalov, A.; Kaeberlein, M.; Soti, C.; Partridge, L.; Gems, D. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila Nature 2011, 477, 482-485
8. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E. A.; Caldwell, S. D.; Napper, A.; Curtis, R.; DiStefano, P. S.; Fields, S.; Bedalov, A.; Kennedy, B. K. Substrate-specific activation of sirtuins by resveratrol J. Biol. Chem. 2005, 280, 17038-17045
9. Borra, M. T.; Smith, B. C.; Denu, J. M. Mechanism of human SIRT1 activation by resveratrol J. Biol. Chem. 2005, 280, 17187-17195
10. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008, 13, 454-463
11. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Oncogene 2009, 28, 781-791
12. Solomon, J. M.; Pasupuleti, R.; Xu, L.; McDonagh, T.; Curtis, R.; DiStefano, P. S.; Huber, L. J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. Cell. Biol. 2006, 26, 28-38
13. Amengual, J. E.; Clark-Garvey, S.; Kalac, M.; Scotto, L.; Marchi, E.; Neylon, E.; Johannet, P.; Wei, Y.; Zain, J.; O'Connor, O. A. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma Blood 2013, 122, 2104-2113
14. Huber, J. L.; McBurney, M. W.; Distefano, P. S.; McDonagh, T. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183 Future Med. Chem. 2010, 2, 1751-1759
15. Carafa, V.; Nebbioso, A.; Altucci, L. Sirtuins and disease: the road ahead Front. Pharmacol. 2012, 3, 4
16. Pacholec, M.; Bleasdale, J. E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R. S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 J. Biol. Chem. 2010, 285, 8340-8351
17. Luo, J.; Nikolaev, A. Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress Cell 2001, 107, 137-148
18. +-dependent tubulin deacetylase Mol. Cell 2003, 11, 437-444
19. Medda, F.; Russell, R. J.; Higgins, M.; McCarthy, A. R.; Campbell, J.; Slawin, A. M.; Lane, D. P.; Lain, S.; Westwood, N. J. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity J. Med. Chem. 2009, 52, 2673-2682
20. Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.; Bedalov, A. Inhibitors of Sir2: evaluation of splitomicin analogues J. Med. Chem. 2004, 47, 2635-2644
21. Neugebauer, R. C.; Uchiechowska, U.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode J. Med. Chem. 2008, 51, 1203-1213
22. Suzuki, T.; Khan, M. N.; Sawada, H.; Imai, E.; Itoh, Y.; Yamatsuta, K.; Tokuda, N.; Takeuchi, J.; Seko, T.; Nakagawa, H.; Miyata, N. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors J. Med. Chem. 2012, 55, 5760-5773
23. Angulo, J.; Nieto, P. M. STD-NMR: application to transient interactions between biomolecules-a quantitative approach Eur. Biophys. J. 2011, 40, 1357-1369
24. Rotili, D.; Carafa, V.; Tarantino, D.; Botta, G.; Nebbioso, A.; Altucci, L.; Mai, A. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile Bioorg. Med. Chem. 2011, 19, 3659-3668
25. Peck, B.; Chen, C. Y.; Ho, K. K.; Di Fruscia, P.; Myatt, S. S.; Coombes, R. C.; Fuchter, M. J.; Hsiao, C. D.; Lam, E. W. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2 Mol. Cancer. Ther. 2010, 9, 844-855
26. Rotili, D.; Tarantino, D.; Nebbioso, A.; Paolini, C.; Huidobro, C.; Lara, E.; Mellini, P.; Lenoci, A.; Pezzi, R.; Botta, G.; Lahtela-Kakkonen, M.; Poso, A.; Steinkuhler, C.; Gallinari, P.; De Maria, R.; Fraga, M.; Esteller, M.; Altucci, L.; Mai, A. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells J. Med. Chem. 2012, 55, 10937-10947
27. Mayer, M.; Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor J. Am. Chem. Soc. 2001, 123, 6108-6117
28. Piotto, M.; Saudek, V.; Sklenar, V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions J. Biomol. NMR. 1992, 2, 661-665
29. 4 Tetrahedron Lett. 2003, 44, 4961-4963
30. Utley, J. H. P.; Rozenberger, G. G. Electroorganic reactions. Part 56: Anodic oxidation of 2-methyl- and 2-benzylnaphthalenes: factors influencing competing pathways Tetrahedron 2002, 58, 5251-5265
31. Wynberg, H.; Meijer, E. W. The Reimer-Teimann reaction Org. React. 1982, 28, 1-36